The Brain Metabolic Change in Chronic Cancer Pain Patient: FDG PET Image Study

Author(s):  
2018 ◽  
Vol 27 (2) ◽  
pp. 715-715
Author(s):  
Martina De Laurentis ◽  
Rossana Botto ◽  
Andrea Bovero ◽  
Riccardo Torta ◽  
Valentina Ieraci

2018 ◽  
Vol 27 (2) ◽  
pp. 705-713
Author(s):  
Martina De Laurentis ◽  
Botto Rossana ◽  
Bovero Andrea ◽  
Torta Riccardo ◽  
Ieraci Valentina

2020 ◽  
Vol 77 (4) ◽  
pp. 1609-1622
Author(s):  
Franziska Mathies ◽  
Catharina Lange ◽  
Anja Mäurer ◽  
Ivayla Apostolova ◽  
Susanne Klutmann ◽  
...  

Background: Positron emission tomography (PET) of the brain with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) is widely used for the etiological diagnosis of clinically uncertain cognitive impairment (CUCI). Acute full-blown delirium can cause reversible alterations of FDG uptake that mimic neurodegenerative disease. Objective: This study tested whether delirium in remission affects the performance of FDG PET for differentiation between neurodegenerative and non-neurodegenerative etiology of CUCI. Methods: The study included 88 patients (82.0±5.7 y) with newly detected CUCI during hospitalization in a geriatric unit. Twenty-seven (31%) of the patients were diagnosed with delirium during their current hospital stay, which, however, at time of enrollment was in remission so that delirium was not considered the primary cause of the CUCI. Cases were categorized as neurodegenerative or non-neurodegenerative etiology based on visual inspection of FDG PET. The diagnosis at clinical follow-up after ≥12 months served as ground truth to evaluate the diagnostic performance of FDG PET. Results: FDG PET was categorized as neurodegenerative in 51 (58%) of the patients. Follow-up after 16±3 months was obtained in 68 (77%) of the patients. The clinical follow-up diagnosis confirmed the FDG PET-based categorization in 60 patients (88%, 4 false negative and 4 false positive cases with respect to detection of neurodegeneration). The fraction of correct PET-based categorization did not differ between patients with delirium in remission and patients without delirium (86% versus 89%, p = 0.666). Conclusion: Brain FDG PET is useful for the etiological diagnosis of CUCI in hospitalized geriatric patients, as well as in patients with delirium in remission.


1992 ◽  
Vol 7 (7) ◽  
pp. 393-399 ◽  
Author(s):  
François Boureau ◽  
François Saudubray ◽  
Christine d'Arnoux ◽  
Jacques Vedrenne ◽  
Marc Estève ◽  
...  

2013 ◽  
Vol 34 (6) ◽  
pp. 540-543 ◽  
Author(s):  
Kuruva Manohar ◽  
Anish Bhattacharya ◽  
Bhagwant R. Mittal
Keyword(s):  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  

Pain ◽  
1997 ◽  
Vol 73 (1) ◽  
pp. 55-69 ◽  
Author(s):  
Rianne de Wit ◽  
Frits van Dam ◽  
Linda Zandbelt ◽  
Anneke van Buuren ◽  
Karin van der Heijden ◽  
...  

2013 ◽  
Vol 2;16 (2;3) ◽  
pp. E107-E111
Author(s):  
Thomas Chai

Intrathecal drug delivery is a mode of analgesic delivery that can be considered in those experiencing both refractory pain and excessive side effects from opioid and adjuvant analgesic use. Delivery of analgesic agents directly to the cerebral spinal fluid allows binding of the drug to receptors at the spinal level. Therefore, a reduced analgesic dosage can be afforded, resulting in reduction of drug side effects due to decreased systemic absorption. Drug delivery into the intrathecal space provides this benefit, yet it does not eliminate the possibility of drug side effects or risks of complications. Complications from this route of administration may be seen in the perioperative period or beyond, including infection, inflammatory mass, bleeding, and catheter or pump dysfunction, among others. This may manifest as new/worsening pain or as a neurologic deficit, such as a sensorimotor change and bladder/bowel dysfunction. Urgent evaluation with a detailed physical examination, device interrogation, and other workup including imaging is called for if symptoms suspicious for device-related problems arise. For the cancer pain patient, the underlying malignancy should also be considered as a potential cause for these new symptoms after intrathecal system implantation. We present 2 such cases of complications in the cancer pain patient after intrathecal drug delivery due to progression of the underlying malignant process rather than to surgical or device-related problems. The first patient had a history of metastatic osteosarcoma who, shortly after undergoing an intrathecal drug delivery trial with external pump, presented with new symptoms of both pain and neurologic changes. The second patient with a history of chondrosarcoma developed new symptoms of pain and sensorimotor change several days after intrathecal drug delivery system implantation. Key words: Intrathecal analgesia, intrathecal drug delivery, perioperative complications, cancer pain, malignant pain, pain pump


2019 ◽  
Vol 41 (5-6) ◽  
pp. 97-106
Author(s):  
Nebojša Lađević ◽  
Vesna Jovanović ◽  
Jelena Jovičić ◽  
Nikola Lađević

2013 ◽  
Vol 29 (6) ◽  
pp. 487-491 ◽  
Author(s):  
Motoo Nomura ◽  
Koichi Inoue ◽  
Shoko Matsushita ◽  
Daisuke Takahari ◽  
Chihiro Kondoh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document